K-Bio·Vaccine No.3 Fund Managers, Daily Partners and NH Investment & Securities

Cumulative Size of K-Bio·Vaccine Fund Reaches 378.6 Billion KRW
Third Fund Managers Selected; Additional Private Capital to Be Raised by May
Fourth and Fifth Funds Planned, Targeting Total of 600 Billion KRW by Year-End

Daily Partners and NH Investment & Securities have been selected as the fund managers for the 3rd K-Bio·Vaccine Fund.

According to the Ministry of Health and Welfare on the 4th, the K-Bio·Vaccine Fund is a fund established with initial capital contributed by the Ministry and policy banks to support innovative new drug development, securing vaccine sovereignty, and the global expansion and mergers & acquisitions (M&A) of domestic pharmaceutical and biohealth companies.

The 3rd fund has secured 40 billion KRW in public contributions from the government and others, and 32 billion KRW in private contributions. It will start investments promptly upon selecting the fund managers and plans to raise additional private capital by May to form a fund worth 100 billion KRW.

With this fund formation, the cumulative size of the K-Bio·Vaccine Fund has reached 378.6 billion KRW, including the 1st fund (Yuanta Investment) with 150 billion KRW and the 2nd fund (Premier Partners) with 156.6 billion KRW.

The 4th and 5th funds are also underway. The Ministry plans to form the 4th fund worth 100 billion KRW, managed by Solidus Investment and IBK Capital, by the end of next month.

Additionally, the Ministry is soliciting fund managers for the 5th fund, also worth 100 billion KRW, and aims to raise a total of 600 billion KRW in funds by the end of this year.

Jung Eun-young, Director of the Health Industry Policy Bureau at the Ministry of Health and Welfare, said, "We hope that the successful final formation of the 3rd K-Bio·Vaccine Fund will serve as a catalyst to drive new drug development and global expansion of domestic pharmaceutical and bio companies."

This content was produced with the assistance of AI translation services.